The first and only full-service, specialty pharmaceutical 3PL solution with cryogenic storage for commercialized cell and gene therapies
An industry-leading solution from a trusted partner
Cell and gene therapies that are creating new possibilities for patients deserve commercialization strategies that are just as pioneering.
An end-to-end platform to help your therapy fulfill its lifesaving promise.
With ICS as your partner, innovators can stay focused on research and development, while we manage the complex-day-to-day logistics.
A seamless solution that scales along with your cell therapy – from many to millions.
We provide the confidence of working with best-in-class partners.
It’s about more than time and temperature.
With the patient in the supply chain, things become more complicated. Ultimately, cell and gene innovators need a coordinated commercialization solution that seamlessly scales infinitely and supports the patient and provider equally. A manufacturer’s primary concern should be continual innovation, not infrastructure building. ICS provides integrated logistics–including cryogenic storage, customer service, order-to-cash financial management and different models for product distribution–all of which can work together to reduce financial risk and operational burden.
Our model of excellence protects the immense value of your molecule to your company and your patients.
As part of AmerisouceBergen – which has businesses at the forefront of each commercialization touch point and a history of supporting the launch of nearly every single biologic and specialty pharmaceutical product that has entered the market over the past 20 years – ICS has a system-wide approach and commitment to excellence in everything we do. Our expertise helps protect the immense value of your cell therapy product at every stage of storage and distribution.
ICS Cryogenic Storage Solution
Start a conversation
Looking for third-party logistics solutions that improve supply chain efficiencies and maximize commercialization success? Contact us to learn more.